Cardio Diagnostics Holdings, Inc.
CDIO Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 27, 2026
$1.70
KIRA · Stoqly’s AI analyst, in plain words
- Cardio Diagnostics Holdings, Inc. had $0.0M of revenue in fiscal 2025, down 57.6% on the year before.
- Its operating margin was −43,811.5%, down 19,840.4 pts: of every 100 in sales, about −43,811 is left after running the business.
- Cardio Diagnostics Holdings, Inc. lost $6.5M in fiscal 2025.
- Free cash flow was −$5.9M in fiscal 2025, −39,960.1% of revenue.
Market cap
$5.0M
P/E
—
Revenue
$0.0M
Net income
−$6.5M
Free cash flow
−$5.9M
Operating margin
−43,811.5%
Cardio Diagnostics Holdings, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−57.6%
No. Sales fell 57.6% last year.
Does it make a profit?
−43,906.8%
No. It lost money last year.
Does profit turn into cash?
−39,960.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cardio Diagnostics Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 13, 2026
- Legal name
- Cardio Diagnostics Holdings, Inc.
- CIK
- 0001870144
Cardio Diagnostics Holdings, Inc. · CDIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Revenue growth | — | 11.1% | 1,610.0% | 104.1% | −57.6% |
| Operating margin | −68,933.3% | −454,850.0% | −42,353.8% | −23,971.1% | −43,811.5% |
| Net income | −$0.6M | −$4.7M | −$8.4M | −$8.4M | −$6.5M |
| Net margin | −68,933.3% | −466,100.0% | −48,987.1% | −24,021.5% | −43,906.8% |
| Diluted EPS | −$0.53 | −$1.51 | −$0.66 | −$9.35 | −$3.71 |
| Cash | |||||
| Cash from operations | −$0.6M | −$5.1M | −$5.7M | −$5.0M | −$5.7M |
| Capital expenditure | — | — | $0.6M | $0.2M | $0.2M |
| Free cash flow | — | — | −$6.2M | −$5.2M | −$5.9M |
| FCF margin | — | — | −36,537.4% | −14,922.3% | −39,960.1% |
| Share count change | — | 165.4% | 310.8% | −92.9% | 95.4% |
| Debt and strength | |||||
| Cash and short-term investments | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $1.1M | $4.3M | $3.0M | $9.6M | $7.0M |
| Current ratio | 6.5x | 3.0x | 3.3x | 13.9x | 9.8x |
| Interest coverage | — | — | −1.1x | −449.8x | −438.1x |
| Returns and quality | |||||
| Return on equity | −58.1% | −173.6% | −230.8% | −134.0% | −78.6% |
| Return on tangible equity | 61.1% | 109.3% | −285.2% | −87.8% | −93.2% |
| Piotroski F-score | — | 0 | 3 | 4 | 1 |
| Altman Z'' | 29.4 | −1.6 | −16.5 | 2.2 | −4.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cardio Diagnostics Holdings, Inc. · CDIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.70 a share, the company is worth $5.0M.
Source: SEC EDGAR XBRL filings (CIK 0001870144). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.